M&A Deal Summary

Haemonetics Acquires Attune Medical

On March 5, 2024, Haemonetics acquired life science company Attune Medical

Acquisition Highlights
  • This is Haemonetics’ 2nd transaction in the Life Science sector.
  • This is Haemonetics’ 12th transaction in the United States.
  • This is Haemonetics’ 4th transaction in Illinois.

M&A Deal Summary
Date 2024-03-05
Target Attune Medical
Sector Life Science
Buyer(s) Haemonetics
Deal Type Add-on Acquisition
Advisor(s) William Blair (Financial)
Perkins Coie (Legal)

Target

Attune Medical

Chicago, Illinois, United States
Attune Medical is a manufacturer of the ensoETM proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency (RF) cardiac ablation procedures. Attune Medical is based in Chicago, Illinois.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Haemonetics

Boston, Massachusetts, United States
Category Company
Founded 1971
Sector Medical Products
Employees2,708
Revenue 1.3B USD (2024)
DESCRIPTION

Haemonetics is a healthcare company dedicated to providing innovative blood management solutions for customers. The company devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients worldwide. Haemonetics was founded in 1971 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 15 of 15
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 14 of 14
State (Illinois) 4 of 4
Country (United States) 12 of 12
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-10-10 OpSens

Quebec City, Quebec, Canada

OpSens is a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. The company offers commercially and clinically validated optical technology for use primarily in interventional cardiology. Its core products include the SavvyWir, a sensor-guided 3-in-1 guidewire for TAVR procedures, that acts as a pacing and pressure monitoring wire advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients, and the OptoWire, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens is based in Quebec City.

Buy $253M
Mergr

Product

Company

Legal